Gene and Stem Cell Therapies Make Strong Showing at ALS/MND Meeting
Trials of gene therapy for spinomuscular atrophy and stem cell treatments for ALS look promising.
6401 RESULTS
Sort By:
Trials of gene therapy for spinomuscular atrophy and stem cell treatments for ALS look promising.
Gene and Stem Cell Therapies Make Strong Showing at ALS/MND Meeting Help for Speech, Swallowing, and Salivation Problems in ALS Does Free Radical Scavenger Edaravone Slow ALS? SOD1, Tau Swept Up in Prion-like Biology at ALS Meeting At the International Sy
Dementia with Lewy Bodies: Is the Research Ready For Clinical Trials Through the Heart? Cardiology Tracer to Nail DLB Diagnosis Dementia with Lewy Bodies: Sharper Image for a Formerly Blurry Disease Brain Imaging: What Does it See in DLB? Lewy Pathology i
At the International Dementia with Lewy Bodies conference in Fort Lauderdale, Florida, fuzzy images of dying sympathetic cardiac nerve terminals proved to be a sharp aide to clinch this notoriously difficult diagnosis.
Studies find that a drug in cough syrup can improve symptoms, and that radiation therapy safely shuts off a salivary gland.
Researchers will follow former football players at risk for the disorder to identify the best biomarkers and clinical criteria.
At a DLB meeting, scientists reported progress in disentangling the notorious overlap in symptoms and pathology in this quintessential spectrum disease. (Hint: tangles are bad.)
How α-synuclein aggregates spread, quite possibly starting in the nose in some people, sets DLB apart from its better-known cousins, Alzheimer’s and Parkinson’s.
When clinicians and pathologists argue, sometimes genetics can settle the dispute. How about DLB?
Alzforum looks back on a year of developments.
The drug benefits some patients with mild amyotrophic lateral sclerosis, and is approved in Japan.
The modified stem cells might slow disease, too, though the trial was too small to say for sure.
The prion concept continues to infiltrate the neurodegeneration field, with models of SOD1 propagation and a bevy of tau strains.
Alzforum spoke with UCSD’s incoming leader for Alzheimer’s research. Where does he want to take the Alzheimer’s Disease Cooperative Study and neurodegeneration research in La Jolla and beyond?
TREM2 levels tracked with tau, but varied widely among patients and carriers of different mutations, leaving it unclear whether TREM2 helps or hurts.